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Abstract
Background
Many maternal traits are associated with a neonate’s gestational duration, birth weight, and
birth length. These birth outcomes are subsequently associated with late-onset health con-
ditions. The causal mechanisms and the relative contributions of maternal and fetal genetic
effects behind these observed associations are unresolved.
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Methods and findings
Based on 10,734 mother–infant duos of European ancestry from the UK, Northern Europe,
Australia, and North America, we constructed haplotype genetic scores using single-nucleo-
tide polymorphisms (SNPs) known to be associated with adult height, body mass index
(BMI), blood pressure (BP), fasting plasma glucose (FPG), and type 2 diabetes (T2D).
Using these scores as genetic instruments, we estimated the maternal and fetal genetic
effects underlying the observed associations between maternal phenotypes and pregnancy
outcomes. We also used infant-specific birth weight genetic scores as instrument and exam-
ined the effects of fetal growth on pregnancy outcomes, maternal BP, and glucose levels
during pregnancy. The maternal nontransmitted haplotype score for height was significantly
associated with gestational duration (p = 2.2 × 10−4). Both maternal and paternal transmitted
height haplotype scores were highly significantly associated with birth weight and length (p
< 1 × 10−17). The maternal transmitted BMI scores were associated with birth weight with a
significant maternal effect (p = 1.6 × 10−4). Both maternal and paternal transmitted BP
scores were negatively associated with birth weight with a significant fetal effect (p = 9.4 ×
10−3), whereas BP alleles were significantly associated with gestational duration and pre-
term birth through maternal effects (p = 3.3 × 10−2 and p = 4.5 × 10−3, respectively). The
nontransmitted haplotype score for FPG was strongly associated with birth weight (p = 4.7 ×
10−6); however, the glucose-increasing alleles in the fetus were associated with reduced
birth weight through a fetal effect (p = 2.2 × 10−3). The haplotype scores for T2D were asso-
ciated with birth weight in a similar way but with a weaker maternal effect (p = 6.4 × 10−3)
and a stronger fetal effect (p = 1.3 × 10−5). The paternal transmitted birth weight score was
significantly associated with reduced gestational duration (p = 1.8 × 10−4) and increased
maternal systolic BP during pregnancy (p = 2.2 × 10−2). The major limitations of the study
include missing and heterogenous phenotype data in some data sets and different instru-
mental strength of genetic scores for different phenotypic traits.
Conclusions
We found that both maternal height and fetal growth are important factors in shaping the
duration of gestation: genetically elevated maternal height is associated with longer gesta-
tional duration, whereas alleles that increase fetal growth are associated with shorter gesta-
tional duration. Fetal growth is influenced by both maternal and fetal effects and can
reciprocally influence maternal phenotypes: taller maternal stature, higher maternal BMI,
and higher maternal blood glucose are associated with larger birth size through maternal
effects; in the fetus, the height- and metabolic-risk–increasing alleles are associated with
increased and decreased birth size, respectively; alleles raising birth weight in the fetus are
associated with shorter gestational duration and higher maternal BP. These maternal and
fetal genetic effects may explain the observed associations between the studied maternal
phenotypes and birth outcomes, as well as the life-course associations between these birth
outcomes and adult phenotypes.
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Author summary
Why was this study done?
• Maternal height, BMI, blood glucose, and blood pressure are associated with gestational
duration, birth weight, and birth length. These birth outcomes are subsequently associ-
ated with late-onset health conditions.
• The causal mechanisms and the relative contributions of maternal and fetal genetic
effects underlying these observed associations are not clear.
What did the researchers do and find?
• We dissected the relative contributions of maternal and fetal genetic effects using haplo-
type genetic score analysis in 10,734 mother–infant pairs of European ancestry.
• Genetically elevated maternal height is associated with longer gestational duration and
larger birth size. In the fetus, alleles associated with adult height are positively associated
with birth size.
• Alleles elevating blood pressure are associated with shorter gestational duration through
a maternal effect and are associated with reduced fetal growth through a fetal genetic
effect. Alleles that increase blood glucose in the mother are associated with increased
birth weight, whereas risk alleles for type 2 diabetes in the fetus are associated with
reduced birth weight.
• Alleles raising birth weight in fetus are associated with shorter gestational duration and
higher maternal blood pressure during pregnancy.
What do these findings mean?
• Maternal size and fetal growth are important factors in shaping the duration of
gestation.
• Fetal growth is influenced by both maternal and fetal effects. Higher maternal BMI and
glucose levels positively associate with birth weight through maternal effects. In the
fetus, alleles associated with higher metabolic risks are negatively associated with birth
weight.
• More rapid fetal growth is associated with shorter gestational duration and higher
maternal blood pressure.
• These maternal and fetal genetic effects can largely explain the observed associations
between maternal phenotypes and birth outcomes, as well as the life-course associations
between these birth outcomes and adult phenotypes.
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Introduction
Epidemiological studies have demonstrated that maternal physical and physiological traits asso-
ciate with birth outcomes. For example, maternal height is positively associated with gestational
duration [1, 2], birth weight, and birth length [3, 4]; higher maternal blood glucose is associated
with higher birth weight [5]; and elevated maternal blood pressure (BP) is associated with
reduced birth weight [6, 7]. These birth outcomes in turn associate with many long-term
adverse health outcomes in the offspring, such as obesity [8], type 2 diabetes (T2D) [9], hyper-
tension [10], and cardiovascular diseases [11, 12]. Different mechanisms have been proposed to
explain the observed associations between maternal phenotypes and pregnancy outcomes [13–
16] (Fig 1A), as well as the life-course associations between birth outcomes and adult pheno-
types [17–20] (Fig 1B). Briefly, these include various causal effects (for example, maternal
effects, defined as the causal influence of the maternal phenotype on birth outcomes or offspring
phenotype [21]), genetically confounded associations due to genetic sharing (between mothers
and infants) or shared genetic effects (between a birth outcome and an adult phenotype) [20],
and confounding due to the environment. Fetal phenotypes can also affect maternal physiology
during or even after pregnancy (fetal drive) [22]. Dissecting these different underlying mecha-
nisms would increase knowledge of the etiology of these critical pregnancy outcomes and pro-
vide insights into how pregnancy outcomes are linked with later-onset disorders [13, 23].
Understanding the causal effects of modifiable maternal phenotypes could have implications
for clinical interventions to prevent adverse birth outcomes [24]. The shared genetic causes
between pregnancy characteristics and late offspring outcomes could provide insights into the
molecular pathways through which these shared genetic effects are mediated [20].
Mendelian randomization (MR) [25] studies utilizing maternal genotypes as instrumental
variables have been used to probe the causal relationships between maternal phenotypes and
pregnancy outcomes [13, 16, 26]. Using this approach, Tyrrell and colleagues [24] demon-
strated that higher maternal body mass index (BMI) and blood glucose levels are causally asso-
ciated with higher birth weight, whereas higher maternal systolic BP (SBP) causes lower birth
weight. Using a genome-wide association (GWA) approach, Horikoshi and colleagues [20]
demonstrated strong inverse genetic correlations between birth weight and adult cardiometa-
bolic diseases, suggesting a strong genetic component underlying the observed associations
between low birth weight and cardiometabolic risks. More recently, Warrington and col-
leagues estimated maternal and fetal genetic effects on birth weight genome-wide and investi-
gated associations between those genetic effects on birth weight and adult SBP [27].
We previously developed an MR method that utilizes nontransmitted maternal alleles as a
valid genetic instrument for maternal phenotypic effects on fetal/offspring outcomes [15]. We
showed that the observed association between maternal height and fetal size is mainly due to
shared genetics, whereas the association between maternal height and gestational duration is
more likely causal. Studies based on this approach have provided novel understandings about the
causal relationships between many maternal phenotypes and birth outcomes. They have also
highlighted genetic contributions to life-course associations between birth weight and late-onset
diseases [20, 27]. However, previous studies have usually examined causal effects of maternal phe-
notypes on either birth weight or gestational duration separately despite the strong association
between them [28, 29]. The studies focusing on birth weight have not explored whether any effects
on birth weight are driven by effects on gestational duration because the information was not
always available. In addition, the causal effects of fetal growth on gestational duration and mater-
nal phenotypes during pregnancy have not been previously investigated using genetic approaches.
To further our understanding of how various maternal phenotypes are correlated with
pregnancy outcomes through maternal or fetal genetic effects and how fetal growth influences
PLOS MEDICINE Maternal and fetal genetic effects on birth outcomes
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gestational duration and maternal physiological changes during pregnancy, we expanded our
haplotype-based method by considering the mother–fetus duo (pregnancy) as the analytical
unit [30] and explicitly modeled maternal and fetal genetic effects using haplotype genetic
scores (Fig 2). By testing associations between these haplotype genetic scores and birth out-
comes, we systematically investigated the maternal and fetal genetic effects underlying the
observed associations between 4 maternal traits (height, BMI, BP, and blood glucose levels)
and pregnancy outcomes (gestational duration, birth weight, and birth length). Using this
approach, we also examined the associations between fetal growth (using gestational-age–
Fig 1. The different mechanisms underlying (A) the associations between maternal phenotypes and pregnancy outcomes and (B) the
associations between pregnancy outcomes and late adult phenotypes in offspring. These mechanisms include 1) causal effects of maternal
phenotypes on pregnancy outcomes (b
m
XY) and causal effects of pregnancy outcomes on adult phenotypes (b
f
YX0 ) (green arrows), 2) genetically
confounded associations between maternal phenotypes and pregnancy outcomes (b
c
XY) because of genetic sharing between mothers and
infants and genetically confounded associations between birth outcomes and adult phenotypes in offspring (b
c
YX0 ) because of shared genetic
effects (blue dashed arrows), 3) confounding due to environmental effects (gray dashed arrows, which were not examined in this study), and 4)
fetal drive (b
f
YX)—fetus causally influencing maternal phenotypes during pregnancy (red arrow).
https://doi.org/10.1371/journal.pmed.1003305.g001
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adjusted birth weight as a measure of this) and pregnancy outcomes, maternal BP, and mater-
nal blood glucose levels measured during pregnancy.
Methods
A prospective protocol for analysis was not prepared for this study; however, the assembly of
the data sets and all the analyses were planned in advance of data analysis. We reported this
study according to the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) guideline [31] for cross-sectional studies (S1 STROBE Checklist). All data derived
from the present study are presented with or in the paper.
Data sets
We used phenotype and genome-wide single-nucleotide polymorphism (SNP) data of 10,734
mother–infant pairs from 6 birth studies (S1 Table). These include 3 case/control data sets
Fig 2. Genetic dissection of maternal and fetal genetic effects using haplotype genetic scores in mother–child
pairs. There are 3 groups of alleles (haplotypes) in a mother (M)–fetus (F) duo: the maternal transmitted alleles (h1)
can affect a pregnancy outcome through a maternal (1) and/or fetal genetic effect (2), the maternal nontransmitted
alleles (h2) can only affect a pregnancy outcome through maternal effect (1), and the paternal transmitted alleles (h3)
only through fetal effect (2) (assuming no paternal effect). The paternal transmitted alleles (h3) could influence a
maternal phenotype during pregnancy by fetal drive (3). The paternal genetics might be able to influence maternal
phenotype and pregnancy outcomes through the environment that the fathers create (i.e., paternal effect or “genetic
nurture”). However, for the traits and their associated variants considered in this study (S2 Table), the paternal effects
should be minimal and therefore were assumed to be zero.
https://doi.org/10.1371/journal.pmed.1003305.g002
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collected from Nordic countries (The Finnish birth data set [FIN], The Mother Child data set
of Norway [MoBa], and The Danish National Birth Cohort [DNBC]) for genetic studies of pre-
term birth [32], a longitudinal birth cohort (the Avon Longitudinal Study of Parents and Chil-
dren [ALSPAC]) [33] from the UK, a study of preterm birth from the US (The Genomic and
Proteomic Network for Preterm Birth Research [GPN]) [34], and the Hyperglycemia and
Adverse Pregnancy Outcome [HAPO] study [5] with samples of European ancestry collected
from the UK, Canada, and Australia. A detailed description of these data sets can be found in
the Supplementary Methods (S1 Text).
We focused on investigating the relationships between maternal height, prepregnancy BMI,
BP, blood glucose levels, and pregnancy outcomes including gestational duration (as both
quantitative and dichotomous preterm/term trait), birth weight, and birth length. Maternal
height, prepregnancy BMI, and the 3 pregnancy outcomes were available in most of the studies
(birth weight and length were not available in the MoBa data used here, and birth length was
not available in the DNBC data used here) (Table 1). Maternal BP during pregnancy was avail-
able in ALSPAC and HAPO. In the HAPO data, BP was measured between 24 and 32 weeks of
pregnancy when the mothers underwent an oral glucose tolerance test (OGTT) [5]. In
ALSPAC, all BP measurements undertaken during antenatal care were extracted from clinical
records; women had a median of 13 (interquartile range 11–16) BP measurements [35]. We
used the average of the BPs measured between 30 to 36 weeks of gestation (as close as possible
to when the BP was measured in HAPO). Maternal fasting plasma glucose (FPG) levels during
pregnancy were available only in the HAPO study. FPG was measured in over 4,000 ALSPAC
mothers in a follow-up data collection 18 years after the pregnancy (S1 Text and Table 1).
Because gestational duration is a key determinant of birth weight and birth size, we only
included pregnancies with spontaneous deliveries and excluded mother–child pairs without
gestational duration information. Pregnancies with known gestational or fetal complications
and pre-existing medical conditions were excluded. Detailed inclusion/exclusion criteria are
provided in Supplementary Methods (S1 Text). Preterm birth was defined as birth before 37
completed weeks of pregnancy.
This study involves reanalysis of existing data sets, and the proposed analytical aims are
consistent with the original consent agreements under which the genomic and phenotypic
data were obtained. Therefore, additional ethics approval was not required.
Genotype data
Genome-wide SNP data were generated using either Affymetrix 6.0 (Affymetrix, Santa Clara,
CA, USA) or various Illumina genotyping arrays (Illumina, San Diego, CA, USA). Standard-
ized genotype quality control procedures were applied to all data sets. Participants of non-
European ancestry were identified and excluded using principal components analysis (PCA)
(S1 Text and S1 Fig). Genome-wide imputation was performed using Minimac3 [36] and the
reference haplotypes from phase 3 of the 1000 Genomes Project [37]. In each data set, the hap-
lotype phasing was done in all maternal and fetal samples using Shapeit2 [38]. This program
accommodates mother–child relationship and accurately estimates mother–child allele trans-
mission when phasing mother–child duos together.
Construction of genetic scores
We constructed weighted genetic scores to instrument various maternal phenotypes using
GWA SNPs and their estimated effect sizes reported by the most recent large GWA studies (S1
Text and S2 Table). Specifically, 2,130 height-associated SNPs and 628 BMI-associated SNPs
reported by the GIANT consortium [39] were used to build genetic scores for height and BMI,
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respectively. Eight hundred thirty-one SNPs associated with BP [40] were used to build genetic
scores for BP. For simplicity, we built a score for average BP using the mean estimated effects
of SBP and diastolic BP (DBP). For FPG, we used 22 SNPs associated with FPG levels identi-
fied in individuals without diabetes [41]. We also constructed a T2D genetic score using 306
T2D SNPs [42] (excluding SNPs overlapping or in close linkage disequilibrium with the 22
FPG SNPs) (S1 Text and S2 Table). To examine the associations of fetal growth (as proxied by
birth weight) with pregnancy outcomes and maternal BP and FPG during pregnancy, we con-
structed genetic scores using 86 SNPs associated with birth weight with confirmed fetal effect
[27]. The lists of these GWA SNPs used in constructing genetic scores are provided in S1 Data.
For each set of GWA SNPs, we constructed 2 genotype genetic scores: Smat (maternal geno-
type score), Sfet (fetal genotype score), and 3 haplotype genetic scores: Sh1, Sh2, and Sh3, respec-
tively, based on the maternal transmitted (h1), maternal nontransmitted (h2), and paternal
transmitted alleles (h3) (Fig 2). It follows that Smat = Sh1 + Sh2 and Sfet = Sh1 + Sh3.
Statistical analyses
Phenotype associations and instrumental strength of genetic scores. We first assessed
the associations between the 4 maternal phenotypes (X) (i.e., height, BMI, BP, and FPG) and
each pregnancy outcome (Y) (i.e., gestational duration, preterm birth, birth weight, and birth
length) using regression analyses. Maternal age, fetal sex, maternal height, and prepregnancy
BMI were included as covariates. Because gestational duration influences birth weight and
length in a nonlinear fashion, the first 3 orthogonal polynomials of gestational duration were
included as covariates in the analysis of birth weight and length. These analytical models are
described in more detail in the Supplementary Methods (S1 Text).
The instrumental strength of the genetic scores was checked by the variance in a maternal
phenotype explained (R2) by the corresponding genetic scores.
Association tests between haplotype genetic scores and pregnancy outcomes. Associa-
tions between the haplotype genetic scores and the pregnancy outcomes were tested using
regression models like those used in the association analysis described above, except that the
maternal phenotypes (X) were replaced by their corresponding 3 haplotype genetic scores (Sh1
+ Sh2 + Sh3). The associations between these haplotype scores can differentiate between mater-
nal and fetal genetic effects (Fig 2). Specifically, an association of Sh2 (maternal nontransmitted
haplotype score) with a pregnancy outcome suggests a maternal (intrauterine phenotypic)
effect, whereas an association of Sh3 (paternal transmitted haplotype score) with the pregnancy
outcomes suggests fetal genetic effects. The 3 haplotype genetic scores of the same mother–
child pairs (Sh1, Sh2, and Sh3) were simultaneously tested in a single-regression model (i.e., Y is
modeled as a function of Sh1 + Sh2 + Sh3 + Cov, where Cov is a list of appropriate covariates),
and hence, they had exactly the same sample size. Therefore, the effect size estimates of these
haplotype scores and their associated p-values can be directly compared to assess the directions
and relative contributions of the maternal and fetal effects.
Modeling of maternal and fetal genetic effects. Whereas Sh2 and Sh3 can be used to draw
inference about maternal and fetal genetic effects, this question can be addressed with greater
statistical power by also including Sh1, the maternal transmitted haplotype score, in the model.
Thus, we modeled the maternal effect and fetal genetic effect as different linear combinations
of the regression coefficients of the 3 haplotype genetic scores (Fig 2 and S1 Text) [30]. Under
the assumptions of additivity between maternal and fetal effect and zero parent-of-origin
effect, the total effect (βh1) of the maternal transmitted haplotype (h1) should be equal to the
summation of the maternal effect (βh2) of the nontransmitted haplotype (h2) and fetal genetic
effect (βh3) of the paternal transmitted haplotype (h3). Thus, (βh1−βh3) and (βh1−βh2),
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respectively, represent the maternal effect and the fetal genetic effect of the maternal transmit-
ted haplotype (h1). Therefore, the average maternal effect (βMY) of the 2 maternal haplotypes
on a birth outcome (Y) can be expressed as (βh1−βh3+ βh2)/2, and the average fetal genetic
effect (βFY) of the maternal and paternal transmitted haplotypes can be expressed as (βh1−βh2+
βh3)/2. Because these linear combinations also capture the maternal or fetal genetic effects of
the maternal transmitted haplotype (h1), they are more powerful than the methods only using
the maternal nontransmitted haplotype (h2) or the paternal transmitted haplotype (h3) as
instruments, respectively, for maternal effect and fetal genetic effect.
Estimation of maternal causal effects. The estimated maternal effect (b^MY) from the hap-
lotype genetic score association analyses can be interpreted as the amount of change in a preg-
nancy outcome (Y) caused by a certain amount of difference in a maternal phenotype (X)
associated with one-unit genetic score. The maternal causal effect (b^mXY) was estimated using
the ratio estimate [43] (b^MY=b^MX), where b^MX is the estimated maternal effect on the maternal
phenotype (Fig 2). As an alternative, we also performed instrumental variable analysis using
the two-stage least-squares (TSLS) approach [43], with the maternal nontransmitted haplotype
score (Sh2) as the genetic instrument for maternal causal effect [15].
Estimation of genetically confounded associations. The fetal genetic effect (βFY) reflects
that the genetic variants associated with an adult phenotype (X0) in the offspring or the corre-
sponding maternal phenotype (X) have direct fetal genetic effect on a pregnancy outcome (Y).
This shared genetic effect can confound the association between a maternal phenotype (X) and
a pregnancy outcome (Y), as well as the association between the pregnancy outcome (Y) and
the adult phenotype (X0) in offspring (Fig 1).
By assuming that all the genetic variants associated with an adult phenotype in offspring
(X0) or the corresponding maternal phenotype (X) have a similar effect on a pregnancy out-
come (Y) as the fetal genetic effect estimated from the genetic score built on known GWA
SNPs (b^FY), we can approximately estimate the magnitude of these genetically confounded
associations (see S1 Text for details). Specifically, the genetically confounded association
between a maternal phenotype (X) and a pregnancy outcome (Y) due to the shared genetic
effect can be estimated by
b^cXY ¼
h2X
2
b^FY
b^MX;
where b^MX is estimated maternal effect and h2X is the heritability (the proportion of additive
genetic variance) of the maternal phenotype (X).
Similarly, the genetically confounded association between a pregnancy outcome (Y) and an
adult (late) phenotype (X0) in offspring can be estimated by
b^cYX0 ¼ h
2 VarðX0Þ
VarðYÞ
b^MY
2þ b^FY
 !
ðMethod 1Þ
and
b^cYX0 ¼ h
2 VarðX0Þ
VarðYÞ
dbh1 þ bh3
2
 !
; ðMethod 2Þ
where h2 is the heritability of the adult phenotype and Var(X0) and Var(Y) are, respectively, the
variance of the adult phenotype and the variance of the pregnancy outcome. The first method
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(Method 1) can partition the confounded association into the maternal (
bMY
2
) and the fetal com-
ponent (βFY) (S1 Text).
Multivariable MR analysis. The genetic scores built on hundreds or thousands of SNPs
are likely to be less specific because they are more likely to be associated with other phenotypic
traits [44], which can introduce ambiguities in the interpretation of genetic score associations
[45]. To circumvent this issue, we performed a two-sample multivariable MR analysis [46, 47]
using the MR pleiotropy residual sum and outlier (MR-PRESSO) [48] to detect and correct for
variants with horizontal pleiotropic effects [49] in multiple-variant MR testing. Three
MR-PRESSO tests were applied: the global test was used to detect the presence of horizontal
pleiotropy, the outlier test to identify variants with significant horizontal pleiotropic effect, and
the distortion test to estimate the distortion caused by significant horizontal pleiotropic outlier
variants. This analysis studies the maternal or fetal genetic effects by testing whether the effects
of the maternal transmitted (h1), maternal nontransmitted (h2), and paternal transmitted (h3)
alleles of the GWA SNPs on a pregnancy outcome are proportional to their reported effects on
an adult phenotype (X0) in the reference GWA studies (S1 Text and S4 Fig). The allele-specific
effect estimates (for the h1, h2, and h3 alleles) of each SNP on a pregnancy outcome were
obtained using the same regression methods for haplotype genetic score analysis (S1 Text).
We did meta-analyses of the results from all available data sets to generate the overall
results. Fixed-effect meta-analysis was used to combine the regression coefficients and stan-
dard errors from individual studies, and we checked between-study heterogeneity using
Cochran’s Q test. The meta-analyses were done using the R metafor package [50].
Results
Phenotypic associations between maternal phenotypes and pregnancy
outcomes
We used 10,734 mother–infant pairs with both genotype and phenotype data in our analyses
(S1 Table). Distributions of key variables for the maternal phenotypes and pregnancy out-
comes are shown in Table 1 and S5–S7 Figs.
The meta-analysis across the 6 data sets showed that taller maternal height was associated
with longer gestational duration (0.14 day/cm, 95% CI: 0.10 to 0.18, p = 2.2 × 10−12), lower pre-
term birth risk (OR = 0.97 /cm, 95% CI: 0.96 to 0.98, p = 2.2 × 10−9), and higher birth weight
(15 g/cm, 95% CI: 13.7 to 16.3, p = 1.5 × 10−111) and length (0.068 cm/cm, 95% CI: 0.061 to
0.075, p = 1.6 × 10−75). Maternal BMI was positively associated with birth weight (15.6 g/[kg/
m2], 95% CI: 13.5 to 17.7, p = 1.0 × 10−47) and birth length (0.05 cm/[kg/m2], 95% CI: 0.04 to
0.06, p = 3.9 × 10−15) but was not associated with gestational duration (0.05 day per kg/m2,
95% CI: −0.01 to 0.11, p = 0.12) or preterm birth risk (OR = 0.99 per kg/m2, 95% CI: 0.98 to
1.01, p = 0.42) (S3 Table).
Using data from ALSPAC and HAPO, we observed that maternal BP during pregnancy was
negatively associated with gestational duration and birth weight. The estimated effect sizes on
gestational duration by SBP and DBP were −0.04 day/mmHg (95% CI: −0.08 to −0.01,
p = 7.3 × 10−3) and −0.11 day/mmHg (95% CI: −0.15 to −0.06, p = 3.3 × 10−6), respectively.
The estimated effect sizes on birth weight by SBP and DBP were −3.0 g/mmHg (95% CI: −4.6
to −1.5, p = 1.8 × 10−4) and −6.2 g/mmHg (95% CI: −8.4 to −3.9, p = 6.0 × 10−8), respectively.
In HAPO, there was a strong positive association between maternal FPG and birth weight (192
g/[mmol/L], 95% CI: 116 to 268, p = 5.7 × 10−7) and birth length (0.62 cm/[mmol/L], 95% CI:
0.27 to 0.97, p = 4.8 × 10−4). However, the association between FPG measured 18 years after
pregnancy with either birth weight or length in the ALSPAC data set was close to zero with
wide confidence intervals (S3 Table).
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Associations between genetic scores and maternal phenotypes
We examined the instrumental strength of the genetic scores for the various maternal pheno-
types. The maternal genotype genetic scores (Smat) were associated with the corresponding
maternal phenotypes and explained a substantial fraction of the phenotypic variances with
similar contributions from the transmitted (h1) or the nontransmitted haplotype scores (h2)
(S4 Table).
The maternal height genotype score (Smat) explained >20% of the maternal height variance
(S5 Table), and the maternal BMI genotype score (Smat) explained approximately 5% of the
maternal BMI variance (S6 Table). The BP genotype scores explained over 2% variance in
maternal BP (S7 Table), which is less than half of the reported fraction of variance explained
by the same score (5.7%) in a published GWA study of nonpregnant women and men (gener-
ally of an older age than pregnant women) [40], suggesting that these BP SNPs have a larger
effect on BP in older populations or a weaker effect on maternal BP during pregnancy.
In HAPO, the maternal FPG genetic score built on 22 SNPs explained 8.3% of the FPG vari-
ance measured between 24–32 weeks. In ALSPAC, the same score explained 4.1% of the vari-
ance of FPG measured 18 years after pregnancy. By contrast, the T2D score (306 SNPs)
explained much less FPG variance (S8 Table).
For each phenotype, we checked the correlations among the various genotype and haplo-
type genetic scores (S9 Table). For height, we observed significant correlations between the
maternal genotype (Smat) and the paternal transmitted haplotype score (Sh3) and between the
maternal transmitted (Sh1) and nontransmitted scores (Sh2), indicating assortative mating [15,
51, 52] and increased homozygosity of height-associated SNPs.
Maternal causal effects and genetically confounded associations between
maternal phenotypes and birth outcomes
We next utilized haplotype genetic scores as genetic instruments to dissect the maternal and
fetal genetic effects underlying the observed associations between maternal phenotypes
and pregnancy outcomes (Table 2). Detailed meta-analysis of individual data sets can be
found in S8–S12 Figs. We also conducted random-effects meta-analyses (S10 Table), and
the results were essentially the same as the results obtained by fixed-effect meta-analyses
(Table 2). To further check the robustness of the results, we conducted the analyses sepa-
rately in ALSPAC (S11 Table) and the other 5 data sets (S12 Table). The results were simi-
lar, except the 5 data sets showed more associations with preterm birth, probably because
these data sets had more preterm pregnancies. Based on the estimated maternal and fetal
genetic effects, we estimated the maternal causal effects and genetically confounded associ-
ations between maternal phenotypes and birth outcomes due to shared genetics (Methods
and Fig 3).
Maternal height. The maternal nontransmitted height genetic score (Sh2) was positively
associated with gestational duration (p = 2.2 × 10−4) and negatively associated with preterm
birth (p = 9.7 × 10−4) (Table 2). The ratio estimates showed a maternal causal effect of approxi-
mately 1.0 days (95% CI: 0.38 to 1.64, p = 1.8 × 10−3) longer gestation per 1-standard deviation
(SD) (6.4 cm) increase in maternal height. This effect was offset by a weaker and opposite fetal
genetic effect of 0.71 days’ (95% CI: 0.07 to 1.35, p = 2.9 × 10−2) shorter gestation per the same
amount of genetic score associated with a 1-SD increase in maternal height (Fig 3 and S13
Table).
Maternal and paternal transmitted haplotype scores (Sh1 and Sh3) for height were positively
associated with birth weight and birth length. The maternal nontransmitted score (Sh2) was
also positively associated with birth weight and length, but the effect estimates were smaller
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than the transmitted haplotype scores (Table 2). The larger effects of transmitted alleles indi-
cate height-associated SNPs can influence growth in early prenatal development through fetal
genetic effect. The estimates for maternal causal and fetal genetic effects were 50 g (95% CI: 29
to 72, p = 5.6 × 10−6) and 111 g (95% CI: 89 to 133, p = 5.0 × 10−23), respectively, for birth
weight and 0.18 cm (95% CI: 0.06 to 0.30, p = 3.3 × 10−3) and 0.59 cm (95% CI: 0.47 to 0.71,
p = 1.0 × 10−21) for birth length per genetic alleles associated with a 1-SD (6.4 cm) increase in
maternal height (Fig 3, S13 Fig, and S13 Table).
Table 2. Association between haplotype genetic scores and birth outcomes.
Maternal Trait (Unit) Haplotype Score
Testsa
Gestational Days Preterm Birth (log[OR]) Birth Weight (g) Birth Length (cm)
Betac SE p-Value Beta SE p-Value Beta SE p-Value Beta SE p-Value
Height (cm)
Maternal transmitted (βh1) 0.038 0.046 0.41 −0.027 0.011 0.016� 20 1.6 6.10 × 10−38� 0.097 0.0087 1.10 × 10−28�
Maternal nontransmitted (βh2) 0.17 0.047 0.00022� −0.037 0.011 0.00097� 6.3 1.6 7.60 × 10−5� 0.022 0.0088 0.011�
Paternal transmitted (βh3) −0.041 0.046 0.37 0.023 0.011 0.038� 14 1.6 3.10 × 10−19� 0.074 0.0085 4.70 × 10−18�
Maternal effect (βMY) 0.13 0.04 0.0017� −0.044 0.0098 9.00 × 10−6� 6.3 1.4 5.20 × 10−6� 0.022 0.0076 0.0033�
Fetal effect (βFY) −0.089 0.041 0.029� 0.016 0.0099 0.1 14 1.4 1.10 × 10−23� 0.074 0.0076 2.70 × 10−22�
BMI (kg/m2)
Maternal transmitted (βh1) −0.059 0.17 0.73 −0.065 0.041 0.11 23 5.8 7.00 × 10−5� 0.066 0.032 0.038�
Maternal nontransmitted (βh2) −0.11 0.17 0.52 0.015 0.041 0.71 8.8 5.8 0.13 0.079 0.032 0.013�
Paternal transmitted (βh3) 0.027 0.17 0.88 0.049 0.04 0.23 −6.5 5.7 0.26 0.027 0.032 0.39
Maternal effect (βMY) −0.098 0.15 0.51 −0.048 0.036 0.18 19 5 0.00016� 0.06 0.028 0.031�
Fetal effect (βFY) 0.043 0.15 0.77 −0.018 0.036 0.6 4 5 0.43 0.0077 0.028 0.78
BPb (mmHg)
Maternal transmitted (βh1) −0.22 0.064 0.00067� 0.034 0.015 0.027� −6.8 2.2 0.0016� −0.018 0.012 0.13
Maternal nontransmitted (βh2) −0.035 0.064 0.59 0.047 0.016 0.0023� −3.1 2.2 0.16 −0.018 0.012 0.13
Paternal transmitted (βh3) −0.016 0.064 0.8 0.005 0.015 0.74 −5.9 2.1 0.0053� −0.017 0.012 0.15
Maternal effect (βMY) −0.12 0.055 0.033� 0.038 0.013 0.0045� −2 1.9 0.27 −0.0096 0.01 0.35
Fetal effect (βFY) −0.1 0.056 0.075 −0.0035 0.013 0.8 −4.8 1.9 0.0094� −0.0086 0.01 0.4
FPG (mmol/L)
Maternal transmitted (βh1) −3.9 1.8 0.029� 0.6 0.43 0.16 13 59 0.82 −0.067 0.32 0.84
Maternal nontransmitted (βh2) −3.2 1.8 0.071 0.54 0.43 0.21 270 59 4.70 × 10−6� 0.71 0.32 0.029�
Paternal transmitted (βh3) 2.7 1.7 0.12 −0.38 0.43 0.37 −52 59 0.38 −0.13 0.32 0.69
Maternal effect (βMY) −5 1.5 0.0012� 0.77 0.37 0.039� 170 51 0.0011� 0.37 0.28 0.19
Fetal effect (βFY) 0.99 1.5 0.51 −0.14 0.36 0.7 −150 50 0.0022� −0.46 0.28 0.096
T2D (log[OR])
Maternal transmitted (βh1) 0.013 0.3 0.97 −0.0079 0.074 0.91 −14 10 0.17 −0.065 0.056 0.25
Maternal nontransmitted (βh2) 0.05 0.31 0.87 0.013 0.072 0.86 33 10 0.0012� 0.059 0.057 0.3
Paternal transmitted (βh3) 0.83 0.31 0.0069� −0.11 0.073 0.13 −28 10 0.0061� −0.033 0.057 0.56
Maternal effect (βMY) −0.39 0.27 0.15 0.058 0.063 0.36 24 8.9 0.0064� 0.015 0.049 0.76
Fetal effect (βFY) 0.4 0.27 0.14 −0.067 0.062 0.28 −39 8.8 1.30 × 10−5� −0.085 0.049 0.082
aβh1, βh2, and βh3 are the effects of the 3 haplotype genetic scores. βMY = (βh1 − βh3 + βh2)/2 and βFY = (βh1 − βh2 + βh3)/2 are, respectively, the maternal and fetal genetic
effects modeled by linear combinations of the haplotype effects.
bBP: mean of the SBP and DBP scores.
cBeta: estimated effects of genetic score associations given by per unit change in genetic scores of the maternal traits.
�p-Values less than 0.05.
Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic BP; SBP, systolic BP; SE, standard error; T2D, type 2 diabetes.
https://doi.org/10.1371/journal.pmed.1003305.t002
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Maternal prepregnancy BMI. BMI haplotype genetic scores were not significantly associ-
ated with gestational duration or preterm birth (Table 2), and the ratio estimates of maternal
causal effects on gestational duration (−0.45 day, 95% CI: −1.80 to 0.89, p = 0.51) and preterm
birth (OR = 0.8, 95% CI: 0.6 to 1.1, p = 0.18) were not significant (S13 Table), suggesting both
minimal maternal and fetal effect of the BMI-associated SNPs on gestational duration. Linear
hypotheses modeling suggested that BMI-associated SNPs have some maternal and no fetal
effect on birth weight and length (Table 2). The estimated maternal causal effect on birth
weight was 88 g (95% CI: 42 to 134, p = 1.9 × 10−4) and on birth length was 0.28 cm (95% CI:
0.02 to 0.53, p = 3.2 × 10−2) per 1-SD (4.0 kg/m2) genetically increased BMI (Fig 3, S13 Fig,
and S13 Table).
Maternal BP. There was a significant association between the maternal nontransmitted
BP genetic score and increased preterm birth risk (p = 2.3 × 10−3), suggesting the association
between maternal BP and gestational duration was primarily driven by a maternal effect
(Table 2). The estimated causal effect sizes based on the ratio method were −2.3 days (95% CI:
−4.4 to −0.14, p = 3.6 × 10−2) on gestational duration and OR = 2.1 (95% CI: 1.2 to 3.5,
p = 5.7 × 10−3) in preterm birth risk per 1-SD (5.8 mmHg) genetically increased maternal BP
(Fig 3, S13 Fig, and S13 Table).
Both maternal transmitted and paternal transmitted BP scores were negatively associated
with birth weight (p = 1.6 × 10−3 and 5.3 × 10−3 for Sh1 and Sh3, respectively; Table 2), suggest-
ing the negative association between maternal BP and birth weight was mainly caused by a
fetal genetic effect. The estimated fetal genetic effect was a reduction of 94 g (95% CI: 21 to
166, p = 1.1 × 10−2) in birth weight by alleles associated with a 1-SD (5.8 mmHg) increase in
maternal BP (Fig 3 and S13 Table).
Maternal FPG. We observed a positive association between maternal nontransmitted
FPG genetic score (Sh2) and birth weight (p = 4.7 × 10−6), indicating a strong causal effect of
increased maternal FPG level on higher birth weight (Table 2). In the HAPO data set, the esti-
mated causal effect size by TSLS based on (Sh2) was 147 g (95% CI: 15 to 279, p = 3.0 × 10−2)
per 1-SD (0.36 mmol/L) increase in maternal FPG, and the ratio estimate in all mother–child
pairs was 59 g (95% CI: 22 to 96, p = 1.8 × 10−3) (S13 Table). Interestingly, but not unexpect-
edly, the linear modeling showed a negative fetal genetic effect of FPG increasing alleles on
birth weight (−54 g, 95% CI: −90 to −18, p = 3.3 × 10−3). The linear hypothesis modeling also
showed a significant negative maternal effect of high maternal FPG on gestational duration
(−1.7 days, 95% CI: −2.8 to −0.6, p = 2.0 × 10−3) and increased risk for preterm birth
(OR = 1.3, 95% CI: 1.0 to 1.7, p = 4.3 × 10−2) per 1-SD (0.36 mmol/L) increase in maternal
FPG (Fig 3, S13 Fig, and S13 Table).
To further understand whether the observed associations were driven by the SNPs that
influence normal FPG levels or by the SNPs associated with pathological hyperglycemia (i.e.,
T2D), we tested associations between the T2D haplotype scores and pregnancy outcomes.
Compared to the FPG scores, the maternal nontransmitted T2D score (Sh2) was less signifi-
cantly associated with both birth weight and gestational duration, but the negative associations
between the paternal transmitted score (Sh3) and birth weight and gestational duration were
more apparent (Table 2).
As shown in Fig 3 and S13 Fig, the combinations of the estimated maternal causal effects
and the genetically confounded associations due to genetic transmission were consistent with
the observed phenotypic associations between maternal phenotypes and birth outcomes. The
maternal causal effects were usually more dominant than the genetically confounded associa-
tions in shaping the phenotypic associations between maternal phenotypes and birth out-
comes. In some cases, the maternal causal effects and the genetically confounded associations
pointed to opposite directions (for example, between height and gestational duration and
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between FPG and birth weight), and in these situations, the estimated maternal causal effects
could be larger than the observed phenotypic associations.
Genetically confounded associations between birth outcomes and adult
phenotypes in offspring
We estimate the magnitude of genetically confounded associations between the birth out-
comes and adult phenotypes (in the offspring) based on the hypothesis that the association was
driven by the variants that were associated with an adult phenotype were also associated with a
birth outcome (Methods). The 2 methods (Method 1 and Method 2) generated similar results
(S14 Table). As shown in Fig 4 and S14 Table, a 1-SD change in birth weight (gestational-age–
adjusted) was estimated to be associated with 0.20 SD (95% CI: 0.17 to 0.24, p = 3.4 × 10−28)
and 0.076 SD (95% CI: 0.014 to 0.138, p = 1.6 × 10−2) differences, respectively, in adult height
and BMI. One-SD increases in both gestational duration and birth weight were estimated to be
associated with a 0.05 SD decrease in adult BP and a 0.025–0.03 SD decrease in adult FPG
level, and birth weight was also estimated to be negatively associated with susceptibility to T2D
(OR = 0.91, 95% CI: 0.85 to 0.98, p = 7.3 × 10−3). The genetically confounded associations
between birth outcomes and adult phenotypes (S14 Fig and S15 Fig) were mainly driven by
the shared genetic effects in offspring; however, the maternal effects could substantially con-
found the associations and point to opposite directions to the confounded associations by fetal
Fig 3. Observed phenotypic associations, estimated maternal causal effects, fetal genetic effects, and genetically confounded associations per 1-SD
change in maternal traits on gestational duration (left) and birth weight (adjusted by gestational duration) (right). The 1-SD values for maternal
traits are 6.4 cm (height), 4.0 kg/m2 (BMI), 5.8 mmHg (BP), and 0.36 mmol/L (FPG). � indicates birth weight adjusted by gestational duration. BMI, body
mass index; BP, blood pressure; FPG, fasting plasma glucose; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1003305.g003
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genetic effects in certain cases (for example, the confounded associations between gestational
duration and height and between birth weight and FPG or T2D risk). We compared the genet-
ically confounded associations between birth weight and adult phenotypes with the estimated
phenotypic associations from genetic correlation [20], the observed associations in the
ALSPAC data, and the reported associations from an epidemiological meta-analysis [53] (Fig
5). The estimated genetically confounded associations using our approach were similar to
those estimated from genetic correlations [20] and were largely consistent with the observed
or reported associations between birth weight and adult phenotypes with the exception of
body height, for which the observed association (from the ALSPAC data) was significantly
stronger than the estimated confounded association due to shared genetics.
Causal effect of fetal growth on gestational duration, maternal BP, and
FPG
To test the possible fetal drive of fetal growth on birth outcomes and maternal pregnancy phe-
notypes, we constructed genetic scores using 86 SNPs associated with birth weight with con-
firmed fetal effect [27] and tested their associations with birth outcomes as well as maternal BP
and FPG during pregnancy (Tables 3 and 4). The fetal genetic score for birth weight was signif-
icantly associated with gestational-age–adjusted birth weight with an R2 = 3.1%. The paternal
transmitted haplotype score (Sh3) consistently has larger effect than the maternal transmitted
score (Sh1) (S15 Table), probably because of a negative maternal effect of the same alleles on
Fig 4. Estimated differences in adult phenotypes (in SDs) per 1-SD difference in birth weight and gestational
duration. The birth weight was adjusted by gestational duration; 1 SD = 426 g. 1 SD of gestational duration was 11.4
days. The 1-SD values for adult phenotypes were assumed to be 6.4 cm (height), 4.0 kg/m2 (BMI), 6.9 mmHg (BP), 0.37
mmol/L (FPG), and 1.81 for log OR of T2D. � indicates birth weight adjusted by gestational duration. BMI, body mass
index; BP, blood pressure; FPG, fasting plasma glucose; SD, standard deviation; T2D, type 2 diabetes.
https://doi.org/10.1371/journal.pmed.1003305.g004
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birth weight and birth length, as shown by the negative effect of the nontransmitted haplotype
score (Sh2) (Table 3). The maternal and paternal transmitted birth weight haplotype scores (Sh1
and Sh3) were also associated with shorter gestational duration and increased preterm birth
risk (Table 3 and S16 Fig). Using the paternal transmitted haplotype score as an instrument,
the estimated causal effects were 3.2 days (95% CI: 1.5 to 5.0, p = 2.7 × 10−4) shorter gestation
and an approximate doubling of the preterm birth risk per 1-SD changes in fetal growth rate
(Table 3). In addition, we also observed significant associations between paternal transmitted
Fig 5. Comparing the magnitudes of genetically confounded associations (differences in adult phenotypes [in
SDs] per 1-SD difference in birth weight) with observed and reported phenotypic associations. Confounded (eff):
genetically confounded associations estimated based on the fetal genetic effect on birth weight (adjusted by gestational
duration) of the variants associated with an adult phenotype. Confounded (cor): genetically confounded associations
between birth weight (unadjusted by gestational duration) and adult phenotype based on the reported genetic
correlations [20]. Observed: observed phenotypic associations between gestational-duration–adjusted birth weight and
offspring height, BMI, BP, and FPG measured at age 17 in ASLPAC. Reported: the reported associations between birth
weight (unadjusted by gestational duration) and BP and T2D susceptibility from a recent epidemiological study [53].
One-SD values in the gestational-duration–adjusted and unadjusted birth weight were 426 g and 484 g, respectively.
BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; SD, standard deviation; T2D, type 2 diabetes.
https://doi.org/10.1371/journal.pmed.1003305.g005
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birth weight score (Sh3) and maternal SBP (p = 2.2 × 10−2) measured during pregnancy and
the estimated causal effects (ratio method) were 1.4 mmHg (95% CI: 0.2 to 2.6, p = 2.3 × 10−2)
increase in SBP per 1-SD changes in fetal growth rate (Table 4 and S17 Fig).
Discussion
In this report, we utilized a haplotype-based genetic score approach to explicitly model the
maternal and fetal genetic effects of maternal phenotypes and pregnancy outcomes (Fig 2).
From the estimated maternal and fetal genetic associations (Table 2), we estimated maternal
causal effects and the genetically confounded associations between maternal phenotypes and
birth outcomes (Fig 3), as well as the genetically confounded associations between birth
Table 3. Associations between birth weight genetic scores and birth outcomes and estimated causal effects per 1-SD change in gestational-age–adjusted birth
weight.
Genetic Score Association and
Causal Estimationa
Gestational Days Preterm Birth (log[OR]) Birth Weight (g) Birth Length (cm)
Beta SE p-Value Beta SE p-Value Beta SE p-Value Beta SE p-Value
Maternal transmitted (βh1) −0.0056 0.0027 0.035� 0.0024 0.00064 0.00018� 0.79 0.087 1.80 × 10−19� 0.0018 0.00048 0.00022�
Maternal nontransmitted (βh2) 0.001 0.0027 0.7 −0.00058 0.00065 0.37 −0.19 0.088 0.029� −0.00022 0.00049 0.66
Paternal transmitted (βh3) −0.0099 0.0026 0.00018� 0.0019 0.00064 0.003� 1.3 0.087 1.70 × 10−48� 0.0031 0.00048 2.30 × 10−10�
Maternal effect (βMY) 0.0026 0.0023 0.26 −5.80 × 10−5 0.00055 0.92 −0.33 0.076 1.10 × 10−5� −0.00073 0.00042 0.082
Fetal effect (βFY) −0.0083 0.0023 0.00029� 0.0025 0.00056 9.20 × 10−6� 1.1 0.075 1.00 × 10−50� 0.0025 0.00042 1.30 × 10−9�
Causal (TSLS) −2.92 0.805 0.00029� 0.837 0.267 0.0017� NA 1.05 0.124 2.40 × 10−17�
Causal (ratio) −3.24 0.889 0.00027� 0.624 0.215 0.0036� 1 0.172 5.10 × 10−9�
aThe effect size (beta) and SEs of genetic score association were given by per unit (g) change in genetic scores; the causal effect sizes were based on per 1-SD (1 SD = 426
g) change in gestational-age–adjusted birth weight. Abbreviations: NA, not applicable; SD, standard deviation; SE, standard error; TSLS, two-stage least-squares.
�p-Values less than 0.05.
https://doi.org/10.1371/journal.pmed.1003305.t003
Table 4. Associations between birth weight genetic scores and maternal BP, glucose levels, and estimated causal
effects per 1-SD changes in gestational-age–adjusted birth weight.
Genetic Score Association
and Causal Estimationa
SBPb (mmHg) DBPb (mmHg) FPGc (mmol/L)
Beta SE p-
Value
Beta SE p-
Value
Beta SE p-
Value
Maternal transmitted (βh1) −0.0026 0.0019 0.17 −0.00021 0.0013 0.87 −0.00011 0.00022 0.61
Maternal nontransmitted
(βh2)
0.00057 0.0019 0.77 0.0006 0.0013 0.65 −0.00025 0.00022 0.26
Paternal transmitted (βh3) 0.0043 0.0019 0.022� 0.0021 0.0013 0.1 8.90 × 10−5 0.00022 0.69
Maternal effect (βMY) −0.0032 0.0016 0.053 −0.00083 0.0011 0.47 −0.00022 0.0002 0.26
Fetal effect (βFY) 0.00054 0.0016 0.74 0.00065 0.0011 0.57 0.00011 0.00019 0.55
Causal (TSLS) 1.2 0.551 0.03� 0.641 0.378 0.09 0.0203 0.0565 0.72
Causal (ratio) 1.41 0.621 0.023� 0.69 0.426 0.1 0.029 0.0724 0.69
aThe effect size (beta) and SEs of genetic score association were given by per unit (g) change in genetic scores; the
causal effect sizes were based on per 1-SD (1 SD = 426 g) change in gestational-age–adjusted birth weight.
Abbreviations: ALSPAC, The Avon Longitudinal Study of Parents and Children; BP, blood pressure; DBP, diastolic
blood pressure; FPG, fasting plasma glucose; HAPO, Hyperglycemia and Adverse Pregnancy Outcome; SBP, systolic
blood pressure; SD, standard deviation; SE, standard error; TSLS, two-stage least-squares.
bMaternal BP (SBP and DBP) in ALSPAC and HAPO.
cFPG during pregnancy measured in HAPO only.
�p-Values less than 0.05.
https://doi.org/10.1371/journal.pmed.1003305.t004
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outcomes and adult phenotypes (Fig 4). We also tested whether fetal growth (as indicated by
gestational-age–adjusted birth weight) could influence gestational duration, maternal BP, and
maternal FPG levels during pregnancy (Tables 3 and 4). Our results revealed complex mater-
nal and fetal genetic effects in shaping the associations between maternal phenotypes and birth
outcomes and their associations with adult phenotypes (Fig 6).
Our results support that maternal height influences the duration of gestation and fetal
growth, and alleles associated with adult height also influence birth size through fetal genetic
effects. These new results support our previous finding [15] with additional evidence. We
observed evidence supporting causal effect of maternal BMI on birth weight and length. Simi-
lar observations have been reported before [24]. We found no evidence demonstrating that
SNPs associated with BMI have significant fetal genetic effects on birth weight or length. We
also observed that alleles elevating BP are associated with shorter gestational duration though a
maternal effect but are associated with reduced fetal growth through a fetal genetic effect. The
later finding is consistent with Horikoshi and colleagues [20]; however, it is inconsistent with
Warrington and colleagues [27], who did not find a fetal effect of alleles for BP on fetal growth.
We showed a positive maternal effect of FPG on fetal growth. This result is consistent with pre-
vious studies [5, 24]. However, the glucose-increasing alleles in the fetus are associated with
reduced birth weight, which is in line with the epidemiological finding that paternal diabetes is
associated with lower birth weight [54] and with the fetal insulin hypothesis [19]. The T2D-
Fig 6. Estimated maternal and fetal genetic effects underlying the associations between maternal phenotypes and pregnancy outcomes and their
associations with adult phenotypes. Blue arrows: maternal or fetal genetic effects. Green arrows: maternal causal effects. Red arrows: “fetal drive.” Dashed
arrows: genetically confounded associations between birth outcomes and late adult phenotypes due to shared genetics. The widths of the arrows were
approximately proportional to the estimated effect sizes evaluated by per-SD changes, which can be found in S13 Table (maternal causal effect), Tables 3 and 4
(fetal drive), and Fig 4 (genetically confounded associations). BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; SD, standard deviation;
T2D, type 2 diabetes
https://doi.org/10.1371/journal.pmed.1003305.g006
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associated SNPs can influence birth weight in a similar way as FPG SNPs but with a weaker
maternal effect and a stronger fetal effect. These observations indicate that the maternal causal
effect is mainly driven by maternal FPG levels. The fetal genetic effect is likely mediated by
fetal insulin, as proposed by the fetal insulin hypothesis [19]. By utilizing the birth weight
genetic score built on paternal transmitted alleles, our findings also support causal effects of
fetal growth on gestational duration and maternal BP.
These findings have several implications. First, maternal size and fetal growth are important
factors in defining the duration of gestation. This is demonstrated not only by the evidence
supporting a causal effect of maternal height (size of the mother) on gestational duration, but
also by the observation that the maternal or fetal genetic effects on fetal growth are usually
associated with opposing effects on gestational duration. For example, rapid fetal growth due
to either high maternal FPG or direct fetal genetic effects of growth-promoting alleles shortens
gestational duration. Whether this “trade-off” between fetal growth and gestational duration is
due to physical [55] or metabolic [56] constraints will require further investigation. Alleles
associated with BP have negative impacts on both birth weight and gestational duration but
mainly through either fetal genetics or a maternal effect, respectively.
Secondly, fetal growth (as evaluated by gestational-duration–adjusted birth weight and
length) is influenced by both maternal and fetal effects. In addition to the positive maternal
effect of maternal FPG on birth weight, the many alleles associated with body height, BP, FPG
level, or T2D susceptibility can influence fetal growth through fetal genetic effects. The alleles
associated with body height are positively associated with birth size, whereas the alleles associ-
ated with higher metabolic risks (for example, high BP, blood glucose level, and higher risk of
T2D) reduce birth weight, which also suggests that lower birth weight (or, more precisely,
small for gestational age status) might be a predictor of the load of genetic metabolic risks. Our
results show that the shared genetic effects largely explain the life-course associations between
birth weight and many cardiometabolic phenotypes (Fig 5), a result that is consistent with the
reported inverse genetic correlations between birth weight and late-onset metabolic disorders
[20], and both support a strong genetic rather than an environmental effect underlying the
life-course association between birth weight and later metabolic risks. Compared with the pre-
vious analyses based on genetic correlations using genome-wide SNPs, our approach estimated
the life-course associations by extrapolating the effects of the top GWA SNPs associated with
the adult phenotypes and therefore has a specific mechanistic implication—the life-course
associations were mainly driven by genetic variants with large effects on adult phenotypes
rather than by the variants with large effects on fetal growth. In addition, our method can par-
tition the genetically confounded associations to either maternal effects or shared genetic
effects in offspring (S1 Text).
The results from this study also reveal a major theme in human pregnancy—both maternal
effects and direct fetal genetic effects jointly shape the observed associations between maternal
phenotypes and pregnancy outcomes. The same genetic variants can influence different birth
outcomes or the same birth outcomes through both maternal and fetal effects, and these 2
types of effects can be antagonistic, as exemplified by the opposing maternal and fetal effects of
the FPG associated alleles on birth weight, or the effects of height-associated alleles on gesta-
tional duration. These complex mechanisms can be further complicated by “fetal drive,” as
shown by the associations between paternal transmitted birth weight genetic score and gesta-
tional duration as well as maternal BP, i.e., fast fetal growth shortens gestational duration and
increases maternal BP (Tables 3 and 4).
Our study had a number of limitations. First, there were some incomplete and heteroge-
neous phenotype data. Most maternal phenotypes (for example, age, height, and BMI) and
birth outcomes (for example, gestational duration and birth weight) were available from the
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study data sets; however, FPG level during pregnancy was only available in HAPO, and BP
data were only available from HAPO and ALSPAC. Another limitation is that because of
incomplete data, we were not able to include important environmental or socioeconomic fac-
tors in the analysis. Some of the maternal exposures (for example, maternal smoking) are
known to be associated with both maternal phenotypes and birth outcomes [57], which may
introduce confounding. However, we argue that the genetic scores used in our study are not
known to be associated with these factors, and therefore, our analyses are robust to potential
confounding due to these environmental factors [58]. Biological pleiotropy is always an issue
in causal inference using genetic instruments, especially when a large number of genetic vari-
ants are used [45, 59]. We used the MR-PRESSO method to detect and remove SNPs with hor-
izontal pleiotropic effects (S1 Text). The results (S16 Table and S17 Table) were essentially the
same as the corresponding haplotype genetic score associations (Tables 2, 3 and 4). There is
some evidence of pleiotropy (MR-PRESSO global test p< 0.05, S18 Table and S19 Table), sug-
gesting the identified maternal effects may be not exclusively mediated by the targeted mater-
nal phenotypes and the fetal effects of the SNPs on a birth outcome are not always
proportional to their report effects on the adult phenotype (S4 Fig). After excluding the outli-
ers, the corrected estimates and the p-values did not change substantially, and all the
MR-PRESSO distortion test p-values were nonsignificant (S18 Table, S19 Table, and S18 Fig).
Multiple maternal and fetal phenotypes were examined in this study. The heritability (S2
Table) and the variance explained by their corresponding genetic scores (S4 Table) varied
across these phenotypic traits. Because of these differences in variance being explained
depending upon phenotype, we had different powers in testing the causal effects or genetic
correlations among these traits. In the analysis of causal effects of fetal growth on maternal BP
and FPG during pregnancy (Table 4), the phenotype data were only available in a subset of
samples, which compromises the power of statistical analyses. These results will benefit from
further replication in independent cohorts. Genetic variants associated with birth weight were
used as genetic instrument for fetal growth. However, birth weight is an endpoint of fetal
growth, and it cannot capture the temporal changes and effects of fetal growth during the
course of pregnancy. Nevertheless, because the major aim of the study is to distinguish and to
compare the relative contributions of maternal and fetal effects, we believe we have provided
robust evidence in support of our major conclusions (Fig 6).
To conclude, our study revealed that many SNPs associated with maternal height, BP, and
blood glucose levels (or T2D susceptibility) can have various maternal and fetal genetic effects
on gestational duration and fetal growth. These maternal and fetal genetic effects may explain
the observed associations between the studied maternal phenotypes and birth outcomes, as
well as the life-course associations between these birth outcomes and adult phenotypes. Our
findings related to gestational-age–adjusted birth weight suggest that rapid fetal growth might
reduce gestational duration and increase maternal BP. These findings provide additional
insights into the mechanisms behind the observed associations between maternal phenotype
and birth outcomes and their life-course impacts on later-life health. Although our current
study focused on pregnancy outcomes measured at birth (for example, gestational duration
and birth weight), similar analysis can be conducted on longitudinal measures (for example,
those related to growth pattern in early life and later adulthood). With the accumulation of
more longitudinal birth cohorts, the dissection of maternal and fetal genetic effects may open
up future opportunities to explore how maternal effect, fetal development, and genetics influ-
ence long-term health and well-being.
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